Back to our people pageBack to Locations

Emmanuel Aisabokhae

Principal

Emmanuel has 15+ years experience in clinical practice, biopharma operations and healthcare consulting, across Europe, Middle East & N. America

Emmanuel Aisabokhae

Areas of Focus

Education

Manchester Business School
MBA
Manchester University
Master of Pharmacy

Past Experience

Arthur D. Little
Healthcare & Life Sciences / Manager
Allagium Therapeutics
Drug development
Johnson & Johnson
R&D/Sales/Marketing/Business Dev
National Health Service, UK
Pharmacist

Emmanuel Aisabokhae

Emmanuel is a Principal based in our New York office. He is a core member of the Healthcare & Lifesciences practice and advises clients on a range of topics including clinical trial acceleration, drug launch preparation and post patent expiry value maximization.

Emmanuel is also a topic expert in pharmacy operations both in the public and private sectors.

Prior to working at Arthur D. Little, Emmanuel worked as a Pharmacist in the UK National Health Service where he gained experience in both public and private sector pharmacy operations, as well as clinical experience across several therapy areas including general medicine, psychiatry, pediatrics, oncology and ophthalmology.

Emmanuel also has multi-function and multi-therapy area experience from Johnson & Johnson Pharmaceuticals and Allagium Therapeutics.  

Emmanuel holds a MBA from Manchester Business School and Master of Pharmacy degree from Manchester University

Why patient centricity is key to long-term pharma company success
Healthcare & life sciences
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
Find out more
Healthcare & life sciences
Elixir of the afterlife
Emmanuel Aisabokhae, Ben Enejo
Find out more
Healthcare & life sciences
Pursuing excellence: What’s next for finance in healthcare?
Vikas Kharbanda, Emmanuel Aisabokhae
Find out more
Healthcare & life sciences
CAR-T on site: Forgoing the extra mile
Emmanuel Aisabokhae, Ben Enejo
CAR-T (chimeric antigen receptor T-cell) therapy involves the use of genetically re-engineered versions of a patient’s own T-cells to find cancer cells and defeat them. As of March 2020, there are two CAR-T therapies licensed for use – Kymriah® and Yescarta®. CAR-T has pushed the boundaries of medicine, and the success observed in patient treatment has created interest in the use of CAR-T to treat a number of other types of tumors. This is evidenced by the number of clinical trials involving the use of CAR-T to treat a range of cancers (Figures below).
Find out more
Healthcare & life sciences
Unleashing the “X factor” in public sector healthcare
Emmanuel Aisabokhae
Find out more
Healthcare & life sciences
Changing gears to deliver CAR-T in your hospital
Emmanuel Aisabokhae, Ben Enejo
Find out more
Healthcare & life sciences
Maximizing the rare chance of launch success with orphan drugs
Emmanuel Aisabokhae, Ben Enejo
Find out more
Healthcare & life sciences
The BIG patent expiry question: Why sink when you can sail?
Emmanuel Aisabokhae, Ben Enejo
As a biopharmaceutical product approaches the end of its patent life, executives believe that the product’s demise is inevitable and will happen at great speed. They begin to worry about the rapid loss of revenue that will be brought about by the entry of generic alternatives into the market. They believe that there are only two outcomes possible for the product: die quickly or die slowly. This fatalistic outlook motivates the selection of a loss-of-exclusivity (LOE) strategy to achieve a slow demise rather than a quick one.
Find out more
Healthcare & life sciences
Pharmacovigilance literature review in the age of precision medicine
Ben Enejo, Emmanuel Aisabokhae
Over the years, pharmacovigilance (PV) processes have involved PV professionals manually going through high volumes of data to identify, assess and report adverse event (AE) information. This set-up will face increasing challenges, as more and more work needs to be done in fixed amounts of time. The options for addressing the challenges can either be labor intensive or technology enabled. Technology-enabled processes have the advantage of being sustainable over time, with the added benefit of potential savings in time and costs.
Find out more

Emmanuel Aisabokhae

Emmanuel is a Principal based in our New York office. He is a core member of the Healthcare & Lifesciences practice and advises clients on a range of topics including clinical trial acceleration, drug launch preparation and post patent expiry value maximization.

Emmanuel is also a topic expert in pharmacy operations both in the public and private sectors.

Prior to working at Arthur D. Little, Emmanuel worked as a Pharmacist in the UK National Health Service where he gained experience in both public and private sector pharmacy operations, as well as clinical experience across several therapy areas including general medicine, psychiatry, pediatrics, oncology and ophthalmology.

Emmanuel also has multi-function and multi-therapy area experience from Johnson & Johnson Pharmaceuticals and Allagium Therapeutics.  

Emmanuel holds a MBA from Manchester Business School and Master of Pharmacy degree from Manchester University

Why patient centricity is key to long-term pharma company success
Healthcare & life sciences
Why patient centricity is key to long-term pharma company success
Patient centricity seems to be an obvious focus for pharmaceutical companies. After all, their core business is to develop drugs and treatments to meet specific patient needs. Yet, patient centricity is not evident across the end-to-end pharma value chain, from identifying unmet patient needs through drug discovery and development to product availability and treatment. For example, on average, 30% of patients leave clinical trials before their scheduled treatment completion date, often because of the high burden of the trials on their lives.
Find out more
Healthcare & life sciences
Elixir of the afterlife
Emmanuel Aisabokhae, Ben Enejo
Find out more
Healthcare & life sciences
Pursuing excellence: What’s next for finance in healthcare?
Vikas Kharbanda, Emmanuel Aisabokhae
Find out more
Healthcare & life sciences
CAR-T on site: Forgoing the extra mile
Emmanuel Aisabokhae, Ben Enejo
CAR-T (chimeric antigen receptor T-cell) therapy involves the use of genetically re-engineered versions of a patient’s own T-cells to find cancer cells and defeat them. As of March 2020, there are two CAR-T therapies licensed for use – Kymriah® and Yescarta®. CAR-T has pushed the boundaries of medicine, and the success observed in patient treatment has created interest in the use of CAR-T to treat a number of other types of tumors. This is evidenced by the number of clinical trials involving the use of CAR-T to treat a range of cancers (Figures below).
Find out more
Healthcare & life sciences
Unleashing the “X factor” in public sector healthcare
Emmanuel Aisabokhae
Find out more
Healthcare & life sciences
Changing gears to deliver CAR-T in your hospital
Emmanuel Aisabokhae, Ben Enejo
Find out more
Healthcare & life sciences
Maximizing the rare chance of launch success with orphan drugs
Emmanuel Aisabokhae, Ben Enejo
Find out more
Healthcare & life sciences
The BIG patent expiry question: Why sink when you can sail?
Emmanuel Aisabokhae, Ben Enejo
As a biopharmaceutical product approaches the end of its patent life, executives believe that the product’s demise is inevitable and will happen at great speed. They begin to worry about the rapid loss of revenue that will be brought about by the entry of generic alternatives into the market. They believe that there are only two outcomes possible for the product: die quickly or die slowly. This fatalistic outlook motivates the selection of a loss-of-exclusivity (LOE) strategy to achieve a slow demise rather than a quick one.
Find out more
Healthcare & life sciences
Pharmacovigilance literature review in the age of precision medicine
Ben Enejo, Emmanuel Aisabokhae
Over the years, pharmacovigilance (PV) processes have involved PV professionals manually going through high volumes of data to identify, assess and report adverse event (AE) information. This set-up will face increasing challenges, as more and more work needs to be done in fixed amounts of time. The options for addressing the challenges can either be labor intensive or technology enabled. Technology-enabled processes have the advantage of being sustainable over time, with the added benefit of potential savings in time and costs.
Find out more

More About Emmanuel
  • Manchester Business School
    MBA
  • Manchester University
    Master of Pharmacy
  • Arthur D. Little
    Healthcare & Life Sciences / Manager
  • Allagium Therapeutics
    Drug development
  • Johnson & Johnson
    R&D/Sales/Marketing/Business Dev
  • National Health Service, UK
    Pharmacist